Clinical trials: Cisplatin, completed
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer
This phase I trial studies the side effects and best dose of veliparib when given together with cisplatin and vinorelbine ditartrate in treating patients with breast cancer that has returned or spread to other parts of the body.
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Hereditary Breast/Ovarian Cancer - BRCA1, Hereditary Breast/Ovarian Cancer - BRCA2
- Trial name
- NCT01104259
- Testing
- veliparib, cisplatin, vinorelbine tartrate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Testicular Cancer, Cardiovascular Diseases
Clinical Characterisation of the Vascular Effects of Cis-platinum Based Chemotherapy in Patients With Testicular Cancer
incidence is increasing1,2. Whilst the prognosis is very good with the vast majority of patients cured with orchidectomy alone, those with high risk stage one non seminomatous germ cell cancer (NSCGT) or metastatic disease (NSCGT…
- Trial name
- VECTOR (NCT03557177)
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- NHS Greater Glasgow and Clyde
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma
First-line Chemotherapy for Recurrent Cervical Cancer
The response rate of traditional first-line chemotherapy for recurrent or persistent advanced cervical cancer was low. This single arm, open, phase II trial would recruit 37 eligible patients.
- Conditions
- Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemotherapy, Vascular Endothelial Growth Factor 2 Inhibitor
- Trial name
- NCT04188847
- Testing
- Chemotherapy plus apatinib
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Lei Li
Anastomotic Leak Esophagus
Anastomotic Leaks in Esophageal Squamous Cell Carcinoma Patients After Trimodal Therapy
To investigate the clinical factors and preoperative treatment to the future anastomotic location of cervical esophagus that were correlated with anastomotic leaks in esophageal squamous cell carcinoma patients undergoing…
- Trial name
- NCT06556355
- Testing
- neoadjuvant chemoradiation and McKeown esophagectomy
- Where
- China
- Volunteers
- 218 people
- Sponsor
- Qiaoqiao Li
Pancreatic Cancer
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004003
- Testing
- cisplatin, fluorouracil, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
High-grade Gliomas
Efficacy and Tolerability of Cisplatin Plus Alternating Weekly Temozolomide in Recurrent High-grade Gliomas
Currently, the prognosis of recurrent high-grade gliomas is still dismal with no standard treatment protocol established. Cisplatin (CDDP), recommended by National Comprehensive Cancer Network (NCCN) as a chemotherapeutic agent…
- Trial name
- NCT02263105
- Testing
- CDDP, Temozolomide
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Huashan Hospital
Stomach Neoplasms, Gastroesophageal Junction Neoplasms
ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction
That panitumumab in combination with Epirubicin, Cisplatin and Capecitabine (ECX) will safely decrease the frequency of pT3/T4 below that of ECX alone in subjects with locally advanced adenocarcinoma of the stomach and…
- Trial name
- NEOPECX (NCT01234324)
- Testing
- Epirubicin, Cisplatin, Capecitabine, Panitumumab, Epirubicin, Cisplatin, Capecitabine
- Where
- Germany
- Volunteers
- 171 people
- Sponsor
- AIO-Studien-gGmbH
Cervical Cancer
Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer
The purpose of this study is to determine whether the combination of topotecan, cisplatin and bevacizumab is effective in the treatment of recurrent or persistent cervical cancer
- Trial name
- NCT00548418
- Testing
- Topotecan, Cisplatin, Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Washington University School of Medicine
Bladder Cancer
Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer
Radical cystectomy remains the gold standard treatment for invasive non metastatic transitional cell cancer (TCC) of the bladder.
- Trial name
- VESPER (NCT01812369)
- Testing
- GEMCITABINE CISPLATINE, METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF
- Where
- France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Rouen
Metastatic Breast Cancer
Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC
Primary objective of this study is to evaluate the efficacy of gemcitabine and cisplatin as first line therapy in patients with triple-negative MBC. 80 patients will be treated into this study.
- Trial name
- NCT00601159
- Testing
- gemcitabine and cisplatin
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Fudan University
Gastrointestinal Neoplasms, Adenocarcinoma
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
The Phase 1b study is an open-label, multicenter dose escalation study designed to assess the safety, tolerability, immunogenicity and recommended phase 2 dose (RP2D) of IMU-131.
- Trial name
- NCT02795988
- Testing
- IMU-131, Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.
- Where
- 22 sites in Georgia, India and 5 more
- Volunteers
- 64 people
- Sponsor
- Imugene Limited
Hepatocellular Carcinoma
Treatment of Portal Vein Tumor Thrombus After Hepatocellular Carcinoma Resection
Hepatectomy is still the treatment of choice for hepatocellular carcinoma. Part of the patients may present portal vein tumor thrombus (PVTT) after resection.
- Trial name
- NCT00825669
- Testing
- TACE, Laser ablation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma…
- Trial name
- NCT03783442
- Testing
- Cisplatin, Oxaliplatin, Fluorouracil (5-FU)
- Where
- 124 sites in United States, Australia and 14 more
- Volunteers
- 649 people
- Sponsor
- BeiGene
Pulmonary Neoplasms
Study of Preoperative Docetaxel or Cisplatin (CDDP) + Docetaxel for C-stage IB-II Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the safety and efficacy of the preoperative docetaxel and docetaxel-cisplatin combination in c-stage IB/II NSCLC, and select the optimal preoperative therapy for phase III trials.
- Trial name
- NCT00132639
- Testing
- Preoperative docetaxel-cisplatin combination chemotherapy, Preoperative docetaxel monotherapy
- Where
- Japan
- Volunteers
- 80 people
- Sponsor
- Haruhiko Fukuda
Malignant Neoplasm of Stomach, Secondary Malignant Neoplasm of Peritoneum
Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis
Patients with histological proven gastric cancer (including cancer of the esophagogastric junction (AEG)) and synchronous peritoneal carcinomatosis, who fulfill the inclusion and exclusion criteria, can be recruited in this…
- Conditions
- Malignant Neoplasm of Stomach, Secondary Malignant Neoplasm of Peritoneum, Secondary Malignant Neoplasm of Other and Unspecified Sites
- Trial name
- GASTRIPEC (NCT02158988)
- Testing
- HIPEC
- Where
- Germany
- Volunteers
- 105 people
- Sponsor
- Charite University, Berlin, Germany
Neuroblastoma
Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00002802
- Testing
- carboplatin, cisplatin, cyclophosphamide
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Advanced Malignant Tumors
A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) and AK117#AntiCD47 Antibody# combined with or without chemotherapy in advanced malignant tumors
- Trial name
- NCT05235542
- Testing
- AK104, AK117, Capecitabine tablets
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Akeso
Neuroblastoma, Ewings Sarcoma
Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas
The main purpose of this study is to determine the short and long term side effects of a very intensive treatment, which includes combinations of chemotherapy drugs followed by radiation therapy and two transplants supported by…
- Conditions
- Neuroblastoma, Ewings Sarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma
- Trial name
- NCT00165139
- Testing
- Vincristine, Cyclophosphamide, Adriamycin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Non Small Cell Lung Cancer Metastatic
A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)
This is a multicenter, single arm, open label phase II study in treatment-naïve for advanced stage of the disease and immunotherapy-naïve patients with advanced non-squamous NSCLC and with < 50% of tumor cells expressing…
- Trial name
- NCT03353675
- Testing
- TG4010, Chemotherapy, Nivolumab
- Where
- 9 sites in United States, Belgium and 2 more
- Volunteers
- 44 people
- Sponsor
- Transgene
Cancer of Head and Neck
Trial Evaluating Adapted Chemotherapy in Patients With Squamous Carcinoma
The objective of this study is to evaluate the efficacity of the combination of cisplatin-5-FU and docetaxel in adapted doses in term of response to treatment without toxicity .
- Trial name
- TPFmORL (NCT04356170)
- Testing
- Docetaxel, Cisplatin, Fluoro Uracil
- Where
- France
- Volunteers
- 105 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.